Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors

CALGARY, Canada, February 1 - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced
today that the Board of Directors has elected Arthur J. Higgins, CEO of
Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee,
to the Board effective February 1, 2010.

Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare
Executive Committee and in 2006 was named Chairman of the Board of Management
of Bayer HealthCare. Mr. Higgins has played a key role in driving the success
of Bayer HealthCare through a combination of strong organic growth and key
acquisitions, including the (euro)17 billion acquisition of the German
pharmaceutical company, Schering AG, in 2006.

"Arthur Higgins' global leadership experience and exposure to numerous
healthcare markets are just a few of the reasons that he is a valued addition
to the Board," said Donald J. McCaffrey, President & CEO of Resverlogix. "As
we progress through our Phase 2 clinical trials, we welcome Mr. Higgins'
perspective as a strategist and R&D specialist."

Mr. Higgins was born in Airdrie, Scotland. He studied at Scotland's
Strathclyde University from 1974 to 1978, where he gained a Bachelor of
Science degree in biochemistry.

Mr. Higgins started his career in 1978 in England with Bristol-Myers. He
subsequently worked for Sandoz (1979 to 1984) and Fisons (1984 to 1987) before
moving to Abbott Laboratories in the USA (1987 to 2001), where he held
various positions of increasing responsibility in the international and
domestic divisions, including a two-year posting in Germany. He was appointed
President of the Pharmaceutical Products Division in Chicago, Illinois, USA,
in 1998. In this position, he was in charge of Abbott's pharmaceuticals
business in the United States with responsibility for global pharmaceutical
research and development.

In 2001, Mr. Higgins was appointed Chairman and CEO of Enzon
Pharmaceuticals headquartered in Bridgewater, New Jersey, USA. In this
function, he also served as Chairman of the Biotech Council of New Jersey and
on the board of the U.S. National Pharmaceutical Council.

Mr. Higgins represents Bayer in the Executive Committee of the
Pharmaceutical Research and Manufacturers of America (PhRMA), and is also a
member of the Council of the International Federation of Pharmaceutical
Manufacturers and Associations (IFPMA).

From May 2007 until December 2009, Mr. Higgins was President of the
European Federation of Pharmaceutical Industries and Associations (EFPIA).

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet medical needs. The NexVas(TM) PR program is the Company's
primary focus which is to develop novel small molecules that enhance ApoA-I.
These vital therapies address the burden of atherosclerosis and other
important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information
please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as
defined under applicable Canadian securities legislation, including our
vision to be a leader in the research, development and commercialization of
novel therapeutics that reduce the risk of cardiovascular disease including
atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and
other vascular diseases. These forward-looking statements contained herein
that are not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate", "forecasts"
and other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the events
or expectations will occur or be realized. By their nature, forward-looking
statements are subject to numerous known and unknown risks and uncertainties
including but not limited to those associated with the success of research
and development programs, clinical trial programs including possible delays
in patient recruitment, the regulatory approval process, competition,
securing and maintaining corporate alliances, market acceptance of the
Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any
financing, reliance on subcontractors and key personnel and additional risk
factors discussed in other documents we file from time to time with
securities authorities, which are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this news
release are expressly qualified by this cautionary statement are
made as of the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise. The TSX Exchange does not accept responsibility
for the adequacy or accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: +1(403)254-9252, Fax: +1(403)256-8495, Email:
Theresa@resverlogix.com; US Investor Relations: Susan Noonan, Managing
Partner, S.A. Noonan Communications, LLC, Phone: +1(212)966-3650, Email:
susan@sanoonan.com

For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1(403)254-9252, Fax: +1(403)256-8495, Email: Theresa at resverlogix.com; US Investor Relations: Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1(212)966-3650, Email: susan at sanoonan.com